1. In Vivo
  2. >>Global Vision

Splits Over Data Protection Could Hamper EU Pharma Revision

 
• By Ian Schofield

The chances of reaching agreement on proposals to overhaul the EU pharma rules before the European Parliament elections in June 2024 are receding as disagreements emerge over key issues such as regulatory data protection and how to encourage antimicrobial R&D.  

divided opinions
• Source: Shutterstock

Lawmakers are gearing up for what could be a long and arduous debate over the European Commission’s proposals for revising the EU pharmaceutical legislation. The revision package, consisting of a draft regulation and a draft directive, is wide-ranging and covers a multitude of areas relating to pharmaceutical regulation. First published in April 2023, it was formally presented to the European Parliament in September.

The contentious nature of many of the proposals bodes ill for a smooth journey through the legislative machinery at the...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Global Vision

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

How Annexon Reclaimed Its Geographic Atrophy Program After Phase II Miss

The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.

Deals Shaping The Industry, August 2025

An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.

Rising Leaders 2025: Noam Solomon’s Quest To Create A ‘Google Maps’ Of the Immune System

 
• By David Wild

The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.